我国九成胃癌发现时为进展期,早诊断早治疗可延长患者生存期

2018-10-14 屠俊 澎湃新闻

根据2010年的统计数据显示,我国胃癌五年生存率是35.9%,而日本、韩国均已达到60%以上,我国胃癌五年生存率仍处于较低水平。而胃癌已经是我国第二大癌症,全世界近一半新发胃癌患者和死亡病例在中国。中国工程院院士、国家消化病临床医学研究中心(上海)主任、长海医院消化内科主任李兆申教授提出,公众对早期胃癌筛查意识薄弱,90%的胃癌患者发现病况时已是进展期 ,错失了最佳诊治时机。10月13日,国家消

根据2010年的统计数据显示,我国癌五年生存率是35.9%,而日本、韩国均已达到60%以上,我国癌五年生存率仍处于较低水平。而胃癌已经是我国第二大癌症,全世界近一半新发胃癌患者和死亡病例在中国。

中国工程院院士、国家消化临床医学研究中心(上海)主任、长海医院消化内科主任李兆申教授提出,公众对早期胃癌筛查意识薄弱,90%的胃癌患者发现病况时已是进展期 ,错失了最佳诊治时机。

10月13日,国家消化道早期防治中心联盟(GECA)宣布,2018全国早期胃癌防治宣传周正式启动,此次宣传周主题为“防治胃癌,从筛查开始”。

启动仪式上,李兆申教授指出,如果胃癌在早期及时筛查,无需“谈癌色变”。在欧美国家,早期胃癌5年生存率可达70%以上,在日韩等国更是高达90%,而晚期胃癌5年生存率则不足10%。如果能早期诊断和治疗,相比晚期胃癌,早期胃癌经规范治疗5年生存率更高,约为90%以上。

此外,导致胃癌发生的最重要可控因素之一——幽门螺杆菌(Hp),通过尿素呼气试验等方法即可确诊,确诊后规范用药就可根除。数据显示,根除幽门螺杆菌可以降低胃癌风险达46% 。因此,李兆申院士强调:早发现早诊断早治疗才是延长胃癌患者生存期的关键,也是提高我国消化道肿瘤防治水平的关键点。

怎样实施既简便又行之有效的早期胃癌筛查策略?既往我国开展的胃癌筛查多依赖胃镜这种侵入性检查,不符合我国人口基数庞大的国情。研究表明,我国40岁以上人群胃癌发生率显着上升,因此在40岁以上高危人群中进行早期胃癌初筛,发现疑似患者再进行精确诊治。

此次活动倡导,40岁以上且符合以下任一条件者都应该进行胃癌筛查 :幽门螺杆菌感染者;胃癌高发地区人群(辽东半岛、山东半岛、长江三角洲、太行山脉和甘肃等地 );既往患有慢性萎缩性胃炎、胃溃疡、胃息肉、手术后残胃、肥厚性胃炎、恶性贫血等胃的癌前病变;胃癌患者一级亲属;存在胃癌其他风险因素(如摄入高盐、腌制饮食、吸烟、重度饮酒等)。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922778, encodeId=99451922e782d, content=<a href='/topic/show?id=eae05949045' target=_blank style='color:#2F92EE;'>#早治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59490, encryptionId=eae05949045, topicName=早治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Sun Jan 20 23:16:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814044, encodeId=0c521814044ca, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Fri Jul 26 14:16:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932639, encodeId=9a31193263934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Jul 21 00:16:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005041, encodeId=23582005041ac, content=<a href='/topic/show?id=1df05950856' target=_blank style='color:#2F92EE;'>#早诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59508, encryptionId=1df05950856, topicName=早诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 20 08:16:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378191, encodeId=848e13e819168, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 16 08:16:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349295, encodeId=57df349295bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:54:05 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922778, encodeId=99451922e782d, content=<a href='/topic/show?id=eae05949045' target=_blank style='color:#2F92EE;'>#早治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59490, encryptionId=eae05949045, topicName=早治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Sun Jan 20 23:16:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814044, encodeId=0c521814044ca, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Fri Jul 26 14:16:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932639, encodeId=9a31193263934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Jul 21 00:16:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005041, encodeId=23582005041ac, content=<a href='/topic/show?id=1df05950856' target=_blank style='color:#2F92EE;'>#早诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59508, encryptionId=1df05950856, topicName=早诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 20 08:16:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378191, encodeId=848e13e819168, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 16 08:16:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349295, encodeId=57df349295bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:54:05 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1922778, encodeId=99451922e782d, content=<a href='/topic/show?id=eae05949045' target=_blank style='color:#2F92EE;'>#早治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59490, encryptionId=eae05949045, topicName=早治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Sun Jan 20 23:16:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814044, encodeId=0c521814044ca, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Fri Jul 26 14:16:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932639, encodeId=9a31193263934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Jul 21 00:16:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005041, encodeId=23582005041ac, content=<a href='/topic/show?id=1df05950856' target=_blank style='color:#2F92EE;'>#早诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59508, encryptionId=1df05950856, topicName=早诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 20 08:16:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378191, encodeId=848e13e819168, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 16 08:16:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349295, encodeId=57df349295bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:54:05 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922778, encodeId=99451922e782d, content=<a href='/topic/show?id=eae05949045' target=_blank style='color:#2F92EE;'>#早治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59490, encryptionId=eae05949045, topicName=早治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Sun Jan 20 23:16:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814044, encodeId=0c521814044ca, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Fri Jul 26 14:16:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932639, encodeId=9a31193263934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Jul 21 00:16:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005041, encodeId=23582005041ac, content=<a href='/topic/show?id=1df05950856' target=_blank style='color:#2F92EE;'>#早诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59508, encryptionId=1df05950856, topicName=早诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 20 08:16:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378191, encodeId=848e13e819168, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 16 08:16:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349295, encodeId=57df349295bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:54:05 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1922778, encodeId=99451922e782d, content=<a href='/topic/show?id=eae05949045' target=_blank style='color:#2F92EE;'>#早治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59490, encryptionId=eae05949045, topicName=早治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Sun Jan 20 23:16:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814044, encodeId=0c521814044ca, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Fri Jul 26 14:16:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932639, encodeId=9a31193263934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Jul 21 00:16:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005041, encodeId=23582005041ac, content=<a href='/topic/show?id=1df05950856' target=_blank style='color:#2F92EE;'>#早诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59508, encryptionId=1df05950856, topicName=早诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 20 08:16:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378191, encodeId=848e13e819168, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 16 08:16:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349295, encodeId=57df349295bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:54:05 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1922778, encodeId=99451922e782d, content=<a href='/topic/show?id=eae05949045' target=_blank style='color:#2F92EE;'>#早治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59490, encryptionId=eae05949045, topicName=早治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Sun Jan 20 23:16:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814044, encodeId=0c521814044ca, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Fri Jul 26 14:16:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932639, encodeId=9a31193263934, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun Jul 21 00:16:00 CST 2019, time=2019-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005041, encodeId=23582005041ac, content=<a href='/topic/show?id=1df05950856' target=_blank style='color:#2F92EE;'>#早诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59508, encryptionId=1df05950856, topicName=早诊断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 20 08:16:00 CST 2018, time=2018-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378191, encodeId=848e13e819168, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Oct 16 08:16:00 CST 2018, time=2018-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=349295, encodeId=57df349295bf, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 14 17:54:05 CST 2018, time=2018-10-14, status=1, ipAttribution=)]
    2018-10-14 医者仁心5538

    学习了

    0

相关资讯

CLIN CANCER RES:Andecaliximab单药或联合mFOLFOX6治疗晚期胃及胃食管交界处腺癌

基质金属蛋白酶-9(MMP9)与促瘤过程密切相关。CLIN CANCER RES近期发表了一篇文章,评估Andecaliximab(GS-5745,一种靶向MMP9的单克隆抗体)单药或联合mFOLFOX6治疗胃癌及胃食管交界处腺癌的疗效。

Genome Biology:南京医科大学发现可作为胃癌治疗潜在靶标的新型LncRNA

近日,南京医科大学德伟等人在Genome Biology杂志发表题为:A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1的研究论文(图1),发现一个新的LncRNA-HOXC-AS3在胃癌组织中显著高表达,并证实HOXC-AS3通过与转录因子YBX1结合,从而

World J Gastrointest Oncol:胃癌分子学、遗传学和免疫特征研究进展

虽然近年胃癌(GC)治疗有很多进步,但多数转移性疾病预后仍很差,因此需要更多基础研究,更好的指导分子靶向治疗和免疫治疗。2014年根据TCGA将GC分为4种分子亚型,然而其转化为临床应用的征途中,结果并不如预期辉煌,2015年根据ACRG同样将GC分为4种亚型,研究显示各亚型与临床结果相关。塞浦路斯Gkolfinopoulos教授在WJGO杂志发文对二种分类进行比较,并对相关临床研究、分子靶向治疗

JAMA Oncology:MUC16突变与更高的肿瘤突变量和更好的胃癌生存相关

胃癌是一类基因异质性较大的疾病,肿瘤突变量(TMLs)存在显著差异。MUC16是胃癌中最常见的突变基因,但其与TML和患者预后的关系尚未明确。来自天津肿瘤医院的研究团队分别在TCGA胃癌队列和亚洲胃癌队列中独立验证了MUC16突变与胃癌突变量和患者生存的关系,并于近期发布在JAMA Oncology杂志上。

中国胃癌发生率显著上升 专家这些中肯倡导应当看一看……

研究表明,中国40岁以上人群胃癌发生率显著上升。

2018 CSCO:知己知彼,论局部进展期胃癌围术期4大定策原则

局部进展期胃癌是临床中常见的胃癌类型,通常可行根治性手术治疗。这一类型的肿瘤定义范围较广,肿瘤异质性较强,目前它的手术、放疗和化疗最佳个体化综合治疗模式仍然存在较大差异,是临床上较为棘手的难题。那么,作为年轻医生的我们,应该如何思考局部进展期胃癌的围术期治疗策略呢?